Lv5
1502 积分 2022-08-31 加入
Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial
22天前
已关闭
LC-MS/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1)
1个月前
已关闭
HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors
1个月前
已完结
HER2-overexpressing/amplified breast cancer as a testing ground for antibody–drug conjugate drug development in solid tumors
1个月前
已关闭
Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement
1个月前
已完结
Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
1个月前
已完结
DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance
1个月前
已完结
Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer
1个月前
已完结
Optimizing the safety of antibody-drug conjugates for patients with solid tumours
2个月前
已完结
Correlation of PSA and survival in metastatic hormone-sensitive prostate cancer treated with rezvilutamide plus ADT in the CHART trial
2个月前
已完结
皖公网安备34019202002308
